Higher radiation dose does not help lung cancer patients live longer

October 3, 2011

A higher dose of radiation (74 Gy) does not improve overall survival for non-small cell lung cancer that has spread to the lymph nodes, compared to the standard radiation dose (60 Gy), according to an interim analysis of a late-breaking randomized study presented at the plenary session, October 3, 2011, at the 53rdAnnual Meeting of the American Society for Radiation Oncology (ASTRO).

"Most and lung cancer specialists are surprised by this finding. Although the optimal radiation dose for has not been tested in a randomized phase III trial for over 30 years, most believed that higher doses of radiation cured more patients with lung cancer," Jeffrey Bradley, MD, a radiation oncologist at the Washington University School of Medicine in St. Louis, said.

The goal of the phase III trial was to find out if high doses of radiation improve survival and also if the chemotherapy drug, Cetuximab, increases survival among stage III non-small cell lung cancer patients. Investigators randomized 423 patients to different doses of radiation therapy and concurrent chemotherapy of paclitaxel and carboplatin with or without Cetuximab. Patients received one of four treatment arms: standard-dose (60 Gy) versus high-dose (74 Gy) radiation therapy and to chemotherapy with or without Cetuximab.

Two types of therapy were used during the trial: three-dimensional conformal radiation therapy (3D-CRT), that uses special imaging techniques to precisely tailor the radiation beams so that nearby normal tissue receives less radiation; and , (IMRT), a newer, specialized form of 3D-CRT which further limits the radiation dose to the normal tissues.

Based on the study's early findings, patients who received the higher dose of radiation (74 Gy) did not have better survival rates than those receiving the standard dose (60 Gy); therefore, the two arms of the trial which used high-dose radiation therapy were closed to patient accrual.

"The trial provides class I evidence that the standard dose of radiation therapy for stage III lung cancer should remain at its existing level of (60 Gy) and doses as high as 74 Gy are not better in curing Stage III lung cancer," Dr. Bradley said. "We are not sure why this is the case and our data is still being carefully reviewed."

Explore further: IMRT has less harmful rectal side effects than 3D-CRT for prostate cancer patients

Related Stories

IMRT has less harmful rectal side effects than 3D-CRT for prostate cancer patients

September 26, 2011
Men with localized prostate cancer treated with a newer technology, intensity modulated radiation therapy (IMRT), have more than a quarter (26 percent) fewer late bowel and rectal side effects and a statistically improved ...

Chemo plus radiation before surgery increases tumor response for rectal cancer

September 26, 2011
Rectal cancer patients who use a new combination of the chemotherapy, Capecitabine, together with five weeks of radiation (50 Gy) before surgery have an 88 percent chance of surviving the cancer three years after treatment, ...

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.